[Therapeutic time window in ischemic stroke].
Katayama
Y
Y
Second Department of Internal Medicine, Nippon Medical School.
Otsubo
K
K
D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives; D004359:Drug Therapy, Combination; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008689:Methacrylates / Q000627:therapeutic use; D010875:Pipecolic Acids / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D013300:Streptokinase / Q000627:therapeutic use; D020521:Stroke / Q000145:classification / Q000628:therapy*; D013449:Sulfonamides; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D008689:Methacrylates; D010875:Pipecolic Acids; D011994:Recombinant Proteins; D013449:Sulfonamides; D006493:Heparin; D001120:Arginine; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; C031942:argatroban; C034364:ozagrel